Thrombospondin-1 deficiency causes a shift from fibroproliferative to inflammatory kidney disease and delays onset of renal failure

American Journal of Pathology

Volumn 184, Issue 10, 2014, Pages 2687-2698

  Zeisberg, Michael ^a,b   Tampe, Björn ^a,b   Lebleu, Valerie ^b,c   Tampe, Desiree ^a,b   Zeisberg, Elisabeth M ^b,d,e   Kalluri, Raghu ^b,c  

^a Departments of Nephrology and Rheumatology   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; COLLAGEN; CREATININE; FIBRILLAR COLLAGEN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 44; RETINOID RELATED ORPHAN RECEPTOR GAMMA; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; AUTOANTIGEN; COLLAGEN TYPE 4; THROMBOSPONDIN-1, MOUSE; TYPE IV COLLAGEN ALPHA3 CHAIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; BIOACCUMULATION; CELL PROLIFERATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; END STAGE RENAL DISEASE; ENZYME ACTIVATION; ENZYME MECHANISM; FIBROBLAST; FIBROGENESIS; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INTERSTITIUM; KNOCKOUT MOUSE; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BLOOD; C57BL MOUSE; CHRONIC KIDNEY FAILURE; DISEASE MODEL; FIBROSIS; KIDNEY; METABOLISM; PATHOLOGY;

ANIMALS; AUTOANTIGENS; COLLAGEN TYPE IV; CREATININE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FIBROSIS; KIDNEY; KIDNEY FAILURE, CHRONIC; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEPHRITIS; RENAL INSUFFICIENCY; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84922455803     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2014.06.014     Document Type: Article

References (39)

1. Zeisberg M, Neilson EG: Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010, 21:1819-1834.
2. McClellan AC, Plantinga L, McClellan WM: Epidemiology, geography and chronic kidney disease. Curr Opin Nephrol Hypertens 2012, 21:323-328.
3. Zeisberg M, Kalluri R: Experimental strategies to reverse chronic renal disease. Blood Purif 2004, 22:440-445.
4. Risdon RA, Sloper JC, De Wardener HE: Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968, 2: 363-366.
5. Bohle A, Bader R, Grund KE, Mackensen S, Neunhoeffer: Serum creatinine concentration and renal interstitial volume. Analysis of correlations in endocapillary (acute) glomerulonephritis and in moderately severe mesangioproliferative glomerulonephritis. Virchows Arch A Pathol Anat Histol 1977, 375:87-96.
6. Bohle A, Glomb D, Grund KE, Mackensen S: Correlation between relative interstitial volume of the renal cortex and serum creatinine concentration in minimal changes with nephrotic syndrome and in focal sclerosing glomerulonephritis. Virchows Arch A Pathol Anat Histol 1977, 376:221-232.
7. Bohle A, Wehrmann M, Bogenschutz O, Batz C, Müller CA, Müller GA: The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 1991, 187:251-259.
8. Armstrong LC, Bornstein P: Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 2003, 22:63-71.
9. Daniel C, Wiede J, Krutzsch HC, Ribeiro SM, Roberts DD, Murphy- Ullrich JE, Hugo C: Thrombospondin-1 is a major activator of TGFbeta in fibrotic renal disease in the rat in vivo. Kidney Int 2004, 65: 459-468.
10. Lu A, Miao M, Schoeb TR, Agarwal A, Murphy-Ullrich JE: Blockade of TSP1-dependent TGF-b activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am J Pathol 2011, 178: 2573-2586.
11. Bige N, Shweke N, Benhassine S, Jouanneau C, Vandermeersch S, Dussaule JC, Chatziantoniou C, Ronco P, Boffa JJ: Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction. Kidney Int 2012, 81:1226-1238.
12. Daniel C, Takabatake Y, Mizui M, Isaka Y, Kawashi H, Rupprecht H, Imai E, Hugo C: Antisense oligonucleotides against thrombospondin-1 inhibit activation of TGF-beta in fibrotic renal disease in the rat in vivo. Am J Pathol 2003, 163:1185-1192.
13. Hochegger K, Knight S, Hugo C, Mayer G, Lawler J, Mayadas TN, Rosenkranz AR: Role of thrombospondin-1 in the autologous phase of an accelerated model of anti-glomerular basement membrane glomerulonephritis. Nephron Exp Nephrol 2004, 96:31-38.
14. Chen H, Herndon ME, Lawler J: The cell biology of thrombospondin-1. Matrix Biol 2000, 19:597-614.
15. Xie L, Duncan MB, Pahler J, Sugimoto H, Martino M, Lively J, Mundel T, Soubasakos M, Rubin K, Takeda T, Inoue M, Lawler J, Hynes RO, Hanahan D, Kalluri R: Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc Natl Acad Sci USA 2011, 108: 9939-9944.
16. Sugimoto H, Mundel TM, Sund M, Xie L, Cosgrove D, Kalluri R: Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci USA 2006, 103:7321-7326.
17. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, Kalluri R: Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamidemediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 2004, 64:1570-1574.
18. Miner JH, Sanes JR: Molecular and functional defects in kidneys of mice lacking collagen alpha 3(IV): Implications for Alport syndrome. J Cell Biol 1996, 135:1403-1413.
19. Zeisberg M, Bottiglio C, Kumar N, Maeshima Y, Strutz F, Müller GA, Kalluri R: Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol 2003, 285:F1060-F1067.
20. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R: Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008, 19:2282-2287.
21. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, SayeghMH, Izumo S, Kalluri R: Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007, 13:952-961.
22. Okuno Y, Huettner CS, Radomska HS, Petkova V, Iwasaki H, Akashi K, Tenen DG: Distal elements are critical for human CD34 expression in vivo. Blood 2002, 100:4420-4426.
23. Zeisberg M, Khurana M, Rao VH, Cosgrove D, Rougier JP, Werner MC, Shield CF 3rd, Werb Z, Kalluri R: Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med 2006, 3:e100.
24. Sugimoto H, Le Bleu VS, Bosukonda D, Keck P, Taduri G, Bechtel W, Okada H, Carlson W Jr, Bey P, Rusckowski M, Tampe B, Tampe D, Kanasaki K, Zeisberg M, Kalluri R: Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med 2012, 18:396-404.
25. Hoffmann KF, McCarty TC, Segal DH, Chiaramonte M, Hesse M, Davis EM, Cheever AW, Meltzer PS, Morse HC 3rd, Wynn TA: Disease fingerprinting with cDNA microarrays reveals distinct gene expression profiles in lethal type 1 and type 2 cytokine-mediated inflammatory reactions. FASEB J 2001, 15:2545-2547.
26. Liu L, Kou P, Zeng Q, Pei G, Li Y, Liang H, Xu G, Chen S: CD4 T lymphocytes, especially Th2 cells, contribute to the progress of renal fibrosis. Am J Nephrol 2012, 36:386-396.
27. Sandler NG, Mentink-Kane MM, Cheever AW, Wynn TA: Global gene expression profiles during acute pathogen-induced pulmonary inflammation reveal divergent roles for Th1 and Th2 responses in tissue repair. J Immunol 2003, 171:3655-3667.
28. Wynn TA: Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004, 4:583-594.
29. Zhang HP, Wu Y, Liu J, Jiang J, Geng XR, Yang G, Mo L, Liu ZQ, Liu ZG, Yang PC: TSP1-producing B cells show immune regulatory property and suppress allergy-related mucosal inflammation. Sci Rep 2013, 3:3345.
30. Yang K, Vega JL, Hadzipasic M, Schatzmann Peron JP, Zhu B, Carrier Y, Masli S, Rizzo LV, Weiner HL: Deficiency of thrombospondin-1 reduces Th17 differentiation and attenuates experimental autoimmune encephalomyelitis. J Autoimmun 2009, 32:94-103.
31. Fu S, Zhang N, Yopp AC, Chen D, Mao M, Zhang H, Ding Y, Bromberg JS: TGF-beta induces Foxp3 T-regulatory cells from CD4 CD25- precursors. Am J Transplant 2004, 4:1614-1627.
32. Gandolfo MT, Jang HR, Bagnasco SM, Ko GJ, Agreda P, Satpute SR, Crow MT, King LS, Rabb H: Foxp3 regulatory T cells participate in repair of ischemic acute kidney injury. Kidney Int 2009, 76:717-729.
33. Kinsey GR, Huang L, Vergis AL, Li L, Okusa MD: Regulatory T cells contribute to the protective effect of ischemic preconditioning in the kidney. Kidney Int 2010, 77:771-780.
34. Wynn TA: Fibrosis under arrest. Nat Med 2010, 16:523-525.
35. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R: BMP-7 counteracts TGF-beta1-induced epithelial-tomesenchymal transition and reverses chronic renal injury. Nat Med 2003, 9:964-968.
36. Schultz-Cherry S, Lawler J, Murphy-Ullrich JE: The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. J Biol Chem 1994, 269:26783-26788.
37. Bechtel W, McGoohan S, Zeisberg EM, Müller GA, Kalbacher H, Salant DJ, Müller CA, Kalluri R, Zeisberg M: Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 2010, 16: 544-550.
38. Christ M, McCartney-Francis NL, Kulkarni AB, Ward JM, Mizel DE, Mackall CL, Gress RE, Hines KL, Tian H, Karlsson S, Wahl SM: Immune dysregulation in TGF-beta 1-deficient mice. J Immunol 1994, 153:1936-1946.
39. Kulkarni AB, Karlsson S: Inflammation and TGF beta 1: lessons from the TGF beta 1 null mouse. Res Immunol 1997, 148:453-456.